Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19

References

• Abernethy, D.R., Kaminsky, L.S., and Dickinson, T.H., 1991. Selective inhibition of warfarin metabolism by diltiazem in humans. The journal of pharmacology and experimental therapeutics, 257 (1), 411–415.
   PubMed Web of Science ®Google Scholar
• Bezerra, L.S., et al., 2018. Impacts of cytochrome P450 2D6 (CYP2D6) genetic polymorphism in tamoxifen therapy for breast cancer. Revista Brasileira de ginecologia e obstetricia, 40 (12), 794–799.
   Web of Science ®Google Scholar
• Bidstrup, T.B., et al., 2003. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. British journal of clinical pharmacology, 56 (3), 305–314.
   PubMed Web of Science ®Google Scholar
• Bird, T.G., et al., 1992. Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model. Journal of medicinal chemistry, 35 (14), 2643–2651.
   PubMed Web of Science ®Google Scholar
• Buchheit, D., et al., 2011. Production of ibuprofen acyl glucosides by human UGT2B7. Drug metabolism and disposition, 39 (12), 2174–2181.
   PubMed Web of Science ®Google Scholar
• Charfi, R., et al., 2018. Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism. La Tunisie medicale, 96 (3), 209–218.
   PubMedGoogle Scholar
• Christensen, S.B., et al., 1998. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. Journal of medicinal chemistry, 41 (6), 821–835.
   PubMed Web of Science ®Google Scholar
• Court, M.H., et al., 2013. The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. The journal of pharmacology and experimental therapeutics, 345 (2), 297–307.
   PubMed Web of Science ®Google Scholar
• Court, M.H., et al., 2017. Race, gender, and genetic polymorphism contribute to variability in acetaminophen pharmacokinetics, metabolism, and protein-adduct concentrations in healthy African-American and European-American volunteers. Journal of pharmacology and experimental therapeutics, 362 (3), 431–440.
   PubMed Web of Science ®Google Scholar
• da Silveira, M., et al., 2019. Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin. The application of clinical genetics, 12, 151–159.
   PubMed Web of Science ®Google Scholar
• Davies, B. and Morris, T., 1993. Physiological parameters in laboratory animals and humans. Pharmaceutical research, 10 (7), 1093–1095.
   PubMed Web of Science ®Google Scholar
• Deguchi, T., et al., 2011. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Drug metabolism and disposition, 39 (5), 820–829.
   PubMed Web of Science ®Google Scholar
• Di, L., et al., 2013. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug metabolism and disposition, 41 (12), 1975–1993.
   PubMed Web of Science ®Google Scholar
• Down, G., et al., 2006. Clinical pharmacology of cilomilast. Clinical pharmacokinetics, 45, 217–233.
   PubMed Web of Science ®Google Scholar
• Eason, C.T., et al., 1988. The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. European journal of drug metabolism and pharmacokinetics, 13 (2), 129–133.
   PubMed Web of Science ®Google Scholar
• Engel, G., et al., 1996. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clinical pharmacology and therapeutics, 59 (6), 613–623.
   PubMed Web of Science ®Google Scholar
• Flora, D.R., et al., 2017. CYP2C9 genotype-dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on R- and S-warfarin and their oxidative metabolites. Journal of clinical pharmacology, 57 (3), 382–393.
   PubMed Web of Science ®Google Scholar
• Gabrielsson, J. and Hjorth, S., 2012. Chapter 7 – principles of inter-species scaling. In: Quantitative pharmacology: an introduction to integrative pharmacokinetic–pharmacodynamic analysis. Stockholm, Sweden: Apotekarsocieteten-Swedish Academy of Pharmaceutical Sciences, 207–249.
   Google Scholar
• Gill, H.J., Tingle, M.D., and Park, B.K., 1995. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. British journal of clinical pharmacology, 40 (6), 531–538.
   PubMed Web of Science ®Google Scholar
• Guengerich, F.P., 2008. Cytochrome p450 and chemical toxicology. Chemical research in toxicology, 21 (1), 70–83.
   PubMed Web of Science ®Google Scholar
• Hosea, N.A., et al., 2009. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. Journal of clinical pharmacology, 49 (5), 513–533.
   PubMed Web of Science ®Google Scholar
• Incecayir, T. and Agabeyoglu, I., 2006. Bioavailability file: lamotrigine. FABAD journal of pharmaceutical sciences, 31, 163–179.
   Google Scholar
• Inoue, K., et al., 2016. Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. European journal of clinical pharmacology, 72 (5), 555–562.
   PubMed Web of Science ®Google Scholar
• Iwasaki, K., et al., 2016. In vivo individual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9. Biopharmaceutics & drug disposition, 37 (6), 379–383.
   PubMed Web of Science ®Google Scholar
• Jones, R.D., et al., 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. Journal of pharmaceutical sciences, 100 (10), 4074–4089.
   PubMed Web of Science ®Google Scholar
• Kamimura, H., 2006. Genetic polymorphism of cytochrome P450s in beagles: possible influence of CYP1A2 deficiency on toxicological evaluations. Archives of toxicology, 80 (11), 732–738.
   PubMed Web of Science ®Google Scholar
• Kaminsky, L.S. and Zhang, Z.Y., 1997. Human P450 metabolism of warfarin. Pharmacology & therapeutics, 73 (1), 67–74.
   PubMed Web of Science ®Google Scholar
• Karaźniewicz-Łada, M., Luczak, M., and Główka, F., 2009. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes. Xenobiotica, 39 (6), 476–485.
   PubMed Web of Science ®Google Scholar
• Kinzig-Schippers, M., et al., 1999. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clinical pharmacology and therapeutics, 65 (3), 262–274.
   PubMed Web of Science ®Google Scholar
• Koehler, S.C., et al., 2006. Marmoset CYP3A21, a model for human CYP3A4: protein expression and functional characterization of the promoter. Xenobiotica, 36 (12), 1210–1226.
   PubMed Web of Science ®Google Scholar
• Korte, S. and Everitt, J., 2019. Chapter 27 – the use of the marmoset in toxicity testing and nonclinical safety assessment studies. In: R. Marini, et al., eds. The common marmoset in captivity and biomedical research. Academic Press, 493–513.
   Google Scholar
• Koyanagi, T., et al., 2014. Age-related pharmacokinetic changes of acetaminophen, antipyrine, diazepam, diphenhydramine, and ofloxacin in male cynomolgus monkeys and beagle dogs. Xenobiotica, 44 (10), 893–901.
   PubMed Web of Science ®Google Scholar
• Koyanagi, T., et al., 2015. Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro–in vivo correlation. Xenobiotica, 45 (4), 312–321.
   PubMed Web of Science ®Google Scholar
• Kroemer, H.K., et al., 1993. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedeberg's archives of pharmacology, 348, 332–337.
   PubMed Web of Science ®Google Scholar
• Kusama, T., et al., 2018. Association with polymorphic marmoset cytochrome P450 2C19 of in vivo hepatic clearances of chirally separated R-omeprazole and S-warfarin using individual marmoset physiologically based pharmacokinetic models. Xenobiotica, 48 (10), 1072–1077.
   PubMed Web of Science ®Google Scholar
• Lai, A.A., et al., 1979. Kinetics of biotransformation of clonazepam to its 7-amino metabolite in the monkey. Journal of pharmacokinetics and biopharmaceutics, 7 (1), 87–95.
   PubMedGoogle Scholar
• Lazarska, K.E., et al., 2018. Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicology letters, 284, 70–78.
   PubMed Web of Science ®Google Scholar
• Lee, C.R., et al., 2003. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. Journal of clinical pharmacology, 43 (1), 84–91.
   PubMed Web of Science ®Google Scholar
• Lombardo, F., et al., 2013a. Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. Journal of clinical pharmacology, 53 (2), 178–191.
   PubMed Web of Science ®Google Scholar
• Lombardo, F., et al., 2013b. Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. The journal of clinical pharmacology, 53 (2), 167–177.
   PubMed Web of Science ®Google Scholar
• Lund, L., et al., 1974. Pharmacokinetics of single and multiple doses of phenytoin in man. European journal of clinical pharmacology, 7 (2), 81–86.
   PubMed Web of Science ®Google Scholar
• Mahmood, I., 2010. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. Journal of pharmaceutical sciences, 99 (7), 2927–2933.
   PubMed Web of Science ®Google Scholar
• Mise, M., et al., 2004. Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug metabolism and disposition, 32 (2), 240–245.
   PubMed Web of Science ®Google Scholar
• Miyamoto, M., et al., 2017. Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. Xenobiotica, 47 (12), 1052–1063.
   PubMed Web of Science ®Google Scholar
• Moise, P.A., Birmingham, M.C., and Schentag, J.J., 2000. Pharmacokinetics and metabolism of moxifloxacin. Drugs of today (Barcelona, Spain: 1998), 36 (4), 229–244.
   PubMed Web of Science ®Google Scholar
• Nakamura, K., et al., 2005. Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biological & pharmaceutical bulletin, 28 (5), 882–885.
   PubMed Web of Science ®Google Scholar
• Nakanishi, K., et al., 2018. In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. Biochemical pharmacology, 152, 272–278.
   PubMed Web of Science ®Google Scholar
• Nelson, M., et al., 2010. Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus). Antimicrobial agents and chemotherapy, 54 (9), 3922–3926.
   PubMed Web of Science ®Google Scholar
• Obach, R.S., et al., 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. The journal of pharmacology and experimental therapeutics, 283 (1), 46–58.
   PubMed Web of Science ®Google Scholar
• Orsi, A., et al., 2011. Overview of the marmoset as a model in nonclinical development of pharmaceutical products. Regulatory toxicology and pharmacology, 59 (1), 19–27.
   PubMed Web of Science ®Google Scholar
• Peng, C.C., et al., 2012. Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals. Drug metabolism and disposition, 40 (3), 426–435.
   PubMed Web of Science ®Google Scholar
• Perel, J.M., et al., 1970. Identification and renal excretion of probenecid metabolites in man. Life sciences. Pt. 1: physiology and pharmacology, 9 (23), 1337–1343.
   PubMedGoogle Scholar
• Persson, B., Heykants, J., and Hedner, T., 1991. Clinical pharmacokinetics of ketanserin. Clinical pharmacokinetics, 20 (4), 263–279.
   PubMed Web of Science ®Google Scholar
• Renwick, A.B., et al., 1998. Metabolism of zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica, 28 (4), 337–348.
   PubMed Web of Science ®Google Scholar
• Ring, B.J., et al., 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. Journal of pharmaceutical sciences, 100 (10), 4090–4110.
   PubMed Web of Science ®Google Scholar
• Sabolovic, N., et al., 2000. Nonsteroidal anti-inflammatory drugs and phenols glucuronidation in Caco-2 cells: identification of the UDP-glucuronosyltransferases UGT1A6, 1A3 and 2B7. Life sciences, 67 (2), 185–196.
   PubMed Web of Science ®Google Scholar
• Sanoh, S., et al., 2015. Predictability of plasma concentration–time curves in humans using single-species allometric scaling of chimeric mice with humanized liver. Xenobiotica, 45 (7), 605–614.
   PubMed Web of Science ®Google Scholar
• Sato, K., et al., 2015. Resequencing of the common marmoset genome improves genome assemblies and gene-coding sequence analysis. Scientific reports, 5, 16894.
   PubMed Web of Science ®Google Scholar
• Schmahl, H.J., Nau, H., and Neubert, D., 1988. The enantiomers of the teratogenic thalidomide analogue EM 12: 1. Chiral inversion and plasma pharmacokinetics in the marmoset monkey. Archives of toxicology, 62 (2–3), 200–204.
   PubMed Web of Science ®Google Scholar
• Shimizu, M., et al., 2014. Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression for common marmoset (Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing. PLoS One, 9 (6), e100936.
   PubMed Web of Science ®Google Scholar
• Shin, K.H., et al., 2013. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clinical pharmacology & therapeutics, 94 (5), 601–609.
   PubMed Web of Science ®Google Scholar
• Soars, M.G., Riley, R.J., and Burchell, B., 2001. Evaluation of the marmoset as a model species for drug glucuronidation. Xenobiotica, 31 (12), 849–860.
   PubMed Web of Science ®Google Scholar
• Tang, H., et al., 2011. Controversy in the allometric application of fixed- versus varying-exponent models: a statistical and mathematical perspective. Journal of pharmaceutical sciences, 100 (2), 402–410.
   PubMed Web of Science ®Google Scholar
• Tang, H. and Mayersohn, M., 2011. Controversies in allometric scaling for predicting human drug clearance: an historical problem and reflections on what works and what does not. Current topics in medicinal chemistry, 11 (4), 340–350.
   PubMed Web of Science ®Google Scholar
• Tenmizu, D., et al., 2006. The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor. Drug metabolism and disposition, 34 (5), 800–806.
   PubMed Web of Science ®Google Scholar
• Toda, A., et al., 2018. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. Xenobiotica, 48 (7), 720–726.
   PubMed Web of Science ®Google Scholar
• Toth, K., et al., 2016. Optimization of clonazepam therapy adjusted to patient's CYP3A status and NAT2 genotype. International journal of neuropsychopharmacology, 19 (12), pyw083.
   PubMed Web of Science ®Google Scholar
• Uehara, S., et al., 2015. Novel marmoset cytochrome P450 2C19 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-warfarin, tolbutamide, flurbiprofen, and omeprazole. Drug metabolism and disposition, 43 (10), 1408–1416.
   PubMed Web of Science ®Google Scholar
• Uehara, S., et al., 2016a. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica, 46 (2), 163–168.
   PubMed Web of Science ®Google Scholar
• Uehara, S., et al., 2016b. Individual differences in metabolic clearance of S-warfarin efficiently mediated by polymorphic marmoset cytochrome P450 2C19 in livers. Drug metabolism and disposition, 44 (7), 911–915.
   PubMed Web of Science ®Google Scholar
• Uehara, S., et al., 2017a. Regio- and stereo-selective oxidation of a cardiovascular drug, metoprolol, mediated by cytochrome P450 2D and 3A enzymes in marmoset livers. Drug metabolism and disposition, 45 (8), 896–899.
   PubMed Web of Science ®Google Scholar
• Uehara, S., et al., 2017b. Marmoset cytochrome P450 3A4 ortholog expressed in liver and small-intestine tissues efficiently metabolizes midazolam, alprazolam, nifedipine, and testosterone. Drug metabolism and disposition, 45 (5), 457–467.
   PubMed Web of Science ®Google Scholar
• Uehara, S., et al., 2017c. Functional characterization and tissue expression of marmoset cytochrome P450 2E1. Biopharmaceutics & drug disposition, 38 (6), 394–397.
   PubMed Web of Science ®Google Scholar
• Uehara, S., et al., 2018. Molecular cloning and tissue distribution of a novel marmoset ABC transporter. Biopharmaceutics & drug disposition, 39 (1), 59–63.
   PubMed Web of Science ®Google Scholar
• Uehara, S., et al., 2019. Survey of drug oxidation activities in hepatic and intestinal microsomes of individual common marmosets, a new nonhuman primate animal model. Current drug metabolism, 20 (2), 103–113.
   PubMed Web of Science ®Google Scholar
• Uehara, S., Uno, Y., and Yamazaki, H., 2020. The marmoset cytochrome P450 superfamily: sequence/phylogenetic analyses, genomic structure, and catalytic function. Biochemical pharmacology, 171, 113721.
   PubMed Web of Science ®Google Scholar
• Ueshima, Y., et al., 1996. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcoholism: clinical and experimental research, 20 (1 Suppl.), 25A–28A.
   PubMed Web of Science ®Google Scholar
• Uno, Y., et al., 2014a. CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques. Biochemical pharmacology, 91 (2), 242–248.
   PubMed Web of Science ®Google Scholar
• Uno, Y., et al., 2014b. Polymorphisms of CYP2D17 in cynomolgus and rhesus macaques: an evidence of the genetic basis for the variability of CYP2D-dependent drug metabolism. Drug metabolism and disposition, 42 (9), 1407–1410.
   PubMed Web of Science ®Google Scholar
• Uno, Y., et al., 2015a. Genetic polymorphism of cynomolgus and rhesus macaque CYP2C9. Drug metabolism and pharmacokinetics, 30 (1), 130–132.
   PubMed Web of Science ®Google Scholar
• Uno, Y., et al., 2015b. CYP2D44 polymorphisms in cynomolgus and rhesus macaques. Molecular biology reports, 42 (7), 1149–1155.
   PubMed Web of Science ®Google Scholar
• Uno, Y., et al., 2018a. Cytochrome P450 1A1, 2C9, 2C19, and 3A4 polymorphisms account for interindividual variability of toxicological drug metabolism in cynomolgus macaques. Chemical research in toxicology, 31 (12), 1373–1381.
   PubMed Web of Science ®Google Scholar
• Uno, Y., et al., 2019. Functional and molecular characterization of UDP-glucuronosyltransferase 2 family in cynomolgus macaques. Biochemical pharmacology, 163, 335–344.
   PubMed Web of Science ®Google Scholar
• Uno, Y., et al., 2020. Molecular characterization of functional UDP-glucuronosyltransferases 1A and 2B in common marmosets. Biochemical pharmacology, 172, 113748.
   PubMed Web of Science ®Google Scholar
• Uno, Y., Matsushita, A., and Yamazaki, H., 2011. CYP1B1 is polymorphic in cynomolgus and rhesus macaques. The journal of veterinary medical science, 73 (9), 1229–1231.
   PubMed Web of Science ®Google Scholar
• Uno, Y. and Osada, N., 2011. CpG site degeneration triggered by the loss of functional constraint created a highly polymorphic macaque drug-metabolizing gene, CYP1A2. BMC evolutionary biology, 11, 283.
   PubMed Web of Science ®Google Scholar
• Uno, Y., Uehara, S., and Yamazaki, H., 2016. Utility of non-human primates in drug development: comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochemical pharmacology, 121, 1–7.
   PubMed Web of Science ®Google Scholar
• Uno, Y., Uehara, S., and Yamazaki, H., 2018b. Genetic polymorphisms of drug-metabolizing cytochrome P450 enzymes in cynomolgus and rhesus monkeys and common marmosets in preclinical studies for humans. Biochemical pharmacology, 153, 184–195.
   PubMed Web of Science ®Google Scholar
• Utoh, M., et al., 2015. Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo. Biochemical pharmacology, 95 (2), 110–114.
   PubMed Web of Science ®Google Scholar
• Utoh, M., et al., 2016. Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica, 46 (12), 1049–1055.
   PubMed Web of Science ®Google Scholar
• Varma, M.V., et al., 2010. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 53 (3), 1098–1108.
   PubMed Web of Science ®Google Scholar
• Wang, L., et al., 2018. Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. Expert review of clinical pharmacology, 11 (9), 917–922.
   PubMed Web of Science ®Google Scholar
• Ward, K.W. and Smith, B.R., 2004a. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug metabolism and disposition, 32 (6), 603–611.
   PubMed Web of Science ®Google Scholar
• Ward, K.W. and Smith, B.R., 2004b. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug metabolism and disposition, 32 (6), 612–619.
   PubMed Web of Science ®Google Scholar
• Wiltshire, H.R., et al., 1997. Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man. Xenobiotica, 27 (6), 557–571.
   PubMed Web of Science ®Google Scholar
• Yamada, A., et al., 2011. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenetics and genomics, 21 (9), 523–530.
   PubMed Web of Science ®Google Scholar
• Yamamoto, Y., et al., 2015. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes. Therapeutic drug monitoring, 37 (2), 229–235.
   PubMed Web of Science ®Google Scholar
• Zhang, T., et al., 2015. Prospective predictions of human pharmacokinetics for eighteen compounds. Journal of pharmaceutical sciences, 104 (9), 2795–2806.
   PubMed Web of Science ®Google Scholar
• Zharikova, O.L., et al., 2009. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochemical pharmacology, 78 (12), 1483–1490.
   PubMed Web of Science ®Google Scholar